Latest Treatment of Crohn's disease Stories
NEW YORK, July 6, 2011 /PRNewswire/ -- Coronado Biosciences, a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer, today announced that it closed a $25.8 million Series C financing led by National Securities Corporation.
BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology.
CHICAGO, May 9, 2011 /PRNewswire/ -- New study findings showed that treatment with STELARAÂ® (ustekinumab) induced and maintained clinical response in patients with moderate to severe Crohn's disease who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist.
Speaking at the UK National Stem Cell Network annual science meeting later today (30 March), Professor Miguel Forte will describe research into a new cell therapy for chronic inflammatory conditions such as Crohn's disease.
SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M.
Researchers at the University of Queensland Diamantina Institute in Brisbane, Australia, have found that a form of spinal arthritis is genetically linked to Inflammatory Bowel Disease.
The inflammatory bowel disorder Crohn's disease produces its own variant of post traumatic stress (PTSD).
SAN DIEGO, Nov.
- To fire mitraille at.